Gyre Therapeutics, Inc. (GYRE): Net Income
$9.88M
Year ended 2025-12-31
-$28.22M
Trailing 12 months to 2026-06-30
+31.8%
3-year compound annual growth
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.88M | -44.8% | 2026-03-13, From 2025-01-01 |
| 2024-12-31 | $17.90M | n/m | 2026-03-13, From 2024-01-01 |
| 2023-12-31 | -$85.48M | n/m | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | $4.31M | n/c | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | -$87.93M | n/m | 2023-03-30, From 2021-01-01 |
| 2020-12-31 | -$56.24M | n/m | 2022-03-31, From 2020-01-01 |
| 2019-12-31 | -$55.18M | n/m | 2021-03-04, From 2019-01-01 |
| 2018-12-31 | -$30.05M | n/m | 2020-02-20, From 2018-01-01 |
| 2017-12-31 | -$21.56M | n/m | 2019-03-08, From 2017-01-01 |
| 2016-12-31 | -$16.95M | n/m | 2018-03-19, From 2016-01-01 |
| 2015-12-31 | -$14.76M | n/m | 2017-03-08, From 2015-01-01 |
| 2014-12-31 | -$6.61M | n/m | 2016-03-09, From 2014-01-01 |
| 2013-12-31 | -$9.97M | n/m | 2016-03-09, From 2013-01-01 |
| 2012-12-31 | -$7.00M | n/m | 2015-03-16, From 2012-01-01 |
| 2011-12-31 | -$8.53M | n/m | 2014-03-14, From 2011-01-01 |
| 2010-12-31 | $10.90M | n/m | 2013-03-15, From 2010-01-01 |
| 2009-12-31 | -$39.40M | n/a | 2012-03-06, From 2009-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $9.88M | -44.8% |
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | -$153.49M | n/m |
| Xencor Inc (XNCR) | 2025-12-31 | -$91.92M | n/m |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $83.23M | n/m |
| Zymeworks Inc. (ZYME) | 2025-12-31 | -$81.13M | n/m |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | -$38.72M | n/m |
| Siga Technologies Inc (SIGA) | 2025-12-31 | $23.28M | -60.7% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | -$196.04M | n/m |
| Elite Pharmaceuticals Inc (ELTP) | 2026-03-31 | $44.87M | n/m |
Compare GYRE, URGN, XNCR, ZVRA side by side · Screen every company in Pharmaceutical Preparations ↗